Quirt J S, Nanji S, Wei X, Flemming J A, Booth C M
Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute.
The departments of Oncology, Queen's University, Kingston, ON.; Surgery, Queen's University, Kingston, ON.
Curr Oncol. 2017 Feb;24(1):e15-e23. doi: 10.3747/co.24.3410. Epub 2017 Feb 27.
The incidence of colon cancer varies by sex. Whether women and men show differences in extent of disease, treatment, and outcomes is not well described. We used a large population-based cohort to evaluate sex differences in colon cancer.
Using the Ontario Cancer Registry, all cases of colon cancer treated with surgery in Ontario during 2002-2008 were identified. Electronic records of treatment identified use of surgery and adjuvant chemotherapy. Pathology reports for a random 25% sample of all cases were obtained, and disease characteristics, treatment, and outcomes in women and men were compared. A Cox proportional hazards model was used to identify factors associated with overall (os) and cancer-specific survival (css).
The study population included 7249 patients who underwent resection of colon cancer; 49% ( = 3556) were women. Stage of disease and histologic grade did not vary by sex. Compared with men, women were more likely to have right-sided disease (55% vs. 44%, ≤ 0.001). Surgical procedure and lymph node yield did not differ by sex. Adjuvant chemotherapy was delivered to 18% of patients with stage ii and 64% of patients with stage iii disease; when adjusted for patient- and disease-related factors, use of adjuvant chemotherapy was similar for women and men [relative risk: 0.99; 95% confidence interval (ci): 0.94 to 1.03]. Adjusted analyses demonstrated that os [hazard ratio (hr): 0.80; 95% ci: 0.75 to 0.86] and css (hr: 0.82; 95% ci: 0.76 to 0.90) were superior for women compared with men.
Long-term survival after colon cancer is significantly better for women than for men, which is not explained by any substantial differences in extent of disease or treatment delivered.
结肠癌的发病率因性别而异。女性和男性在疾病范围、治疗方法和治疗结果方面是否存在差异,目前尚无详尽描述。我们使用了一个基于人群的大型队列来评估结肠癌中的性别差异。
利用安大略癌症登记处,确定了2002年至2008年期间在安大略接受手术治疗的所有结肠癌病例。治疗的电子记录确定了手术和辅助化疗的使用情况。获取了所有病例中随机抽取的25%样本的病理报告,并比较了女性和男性的疾病特征、治疗方法和治疗结果。使用Cox比例风险模型来确定与总生存期(OS)和癌症特异性生存期(CSS)相关的因素。
研究人群包括7249例接受结肠癌切除术的患者;49%(n = 3556)为女性。疾病分期和组织学分级不存在性别差异。与男性相比,女性更易患右侧疾病(55%对44%,P≤0.001)。手术方式和淋巴结切除数量不存在性别差异。18%的II期患者和64%的III期患者接受了辅助化疗;在对患者和疾病相关因素进行调整后,女性和男性辅助化疗的使用情况相似[相对风险:0.99;95%置信区间(CI):0.94至1.03]。经调整分析表明,女性的总生存期(风险比[HR]:0.80;95%CI:0.75至0.86)和癌症特异性生存期(HR:0.82;95%CI:0.76至0.90)均优于男性。
结肠癌患者中,女性的长期生存率显著高于男性,这无法用疾病范围或所接受治疗的任何实质性差异来解释。